Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xoma Corp.

www.xoma.com

Latest From Xoma Corp.

Deal Watch: Lilly, AbCellera Partner To Attempt Rapid COVID-19 Antibody Development

Partnership will combine AbCellera’s screening of antibodies to the virus with Lilly’s development, commercial capabilities. Vir adds Biogen tie-up to its ongoing coronavirus efforts.

Deals Coronavirus COVID-19

Zydus Cadila Joins IO Therapy League With XOMA Tie-up

Cadila Healthcare has entered the immuno-oncology race by inking a licensing agreement with US-based XOMA for a drug candidate that combines the Indian firm's interleukin-2 with the latter’s novel anti-IL-2 monoclonal antibody

Commercial Research & Development

Finance Watch: Recent Offerings Show Some Companies Were Ready For The Government Shutdown

Public Company Edition: The usual mid-January surge in public offerings hasn't happened this year, since the SEC can't process new filings, but Alnylam, Acceleron and others apparently were prepared for a lengthy shutdown. Also, ARM reports cell and gene therapy financing data.

Financing Business Strategies

Finance Watch: Lots Of Money, Big And Small, Flowing Into Drug Development

Big venture capital bets continue in biopharma, including Foresite's new $668m fund and Merck's $125m investment in Moderna, but small VC rounds could be making a comeback. In public company financings, Aslan and Evelo launched in the US, while Ascletis is testing Hong Kong’s IPO market.

Financing StartUps and SMEs
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
    • Synthesis Technologies, Production Processes
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Dermatology
  • Inflammation
  • Metabolic Disorders
  • Alias(es)
  • Xoma Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Xoma Corp.
  • Senior Management
  • James R Neal, CEO
    Tom Burns, SVP, Fin. & CFO
    Kirk Johnson, PhD, VP, Dev.
    Dee Datta, PhD, CBO
  • Contact Info
  • Xoma Corp.
    Phone: (510) 204-7200
    2910 Seventh St.
    Berkeley, CA 94710
    USA
UsernamePublicRestriction

Register